SMILES string
NC(Cc1cc(c(cc1)O)OC)C(=O)O
InChI
1S/C10H13NO4/c1-15-9-5-6(2-3-8(9)12)4-7(11)10(13)14/h2-3,5,7,12H,4,11H2,1H3,(H,13,14)
InChI key
PFDUUKDQEHURQC-UHFFFAOYSA-N
grade
pharmaceutical primary standard
API family
levodopa
manufacturer/tradename
USP
application(s)
pharmaceutical (small molecule)
format
neat
storage temp.
2-8°C
正在寻找类似产品? 访问 产品对比指南
General description
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
Application
Levodopa Related Compound B USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.
Also, for use with USP monographs such as:
Also, for use with USP monographs such as:
- Carbidopa and Levodopa Orally Disintegrating Tablets
- Levodopa
- Carbidopa and Levodopa Tablets
- Carbidopa and Levodopa Extended-Release Tablets
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Other Notes
Sales restrictions may apply.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
No data available
flash_point_c
No data available
Thomas Müller et al.
Clinical neuropharmacology, 36(2), 52-54 (2013-03-19)
Levodopa (LD)/dopa decarboxylase inhibitor application increases 3-O-methyldopa (3-OMD) concentrations in association with methyl group transfers, which demand for the conversion of methionine to homocysteine. This accompanying reaction is partially reversible by methyl group-donating vitamins. The objective of this study was
T Müller et al.
Journal of neural transmission (Vienna, Austria : 1996), 114(3), 347-350 (2006-08-26)
Levodopa (LD) application improves motor symptoms in patients with Parkinson's disease (PD) patients. Little is known on further effects of LD, which induced lower plasma levels of cortisol and lower serotonergic activity in certain brain areas of fish. Objectives of
Christoph Saxer et al.
Journal of chromatography. B, Analytical technologies in the biomedical and life sciences, 802(2), 299-305 (2004-03-17)
A simple and rapid assay is described for the simultaneous analysis of levodopa (l-DOPA) and 3-O-methyldopa (3-OMD) in human plasma samples, applying an ion-pair reversed-phase liquid chromatographic method with electrochemical detection, designed for clinical trials performed to study the effect
Teresa Nunes et al.
Clinical therapeutics, 31(10), 2258-2271 (2009-11-20)
Nebicapone is a reversible catechol-O-methyltransferase (COMT) inhibitor. Coadministration of a COMT inhibitor with levodopa and a dopa-decarboxylase inhibitor (carbidopa or benserazide) increases levodopa exposure and its therapeutic effect. The primary objective of this study was to investigate the effect of
Dag Nyholm et al.
The AAPS journal, 15(2), 316-323 (2012-12-12)
Motor complications of Parkinson's disease (PD) are a consequence of pulsatile dopaminergic stimulation from standard oral levodopa therapy. Levodopa-carbidopa intestinal gel (LCIG) is infused continuously via an intrajejunal percutaneous gastrostomy tube. This was the first study designed to characterize the
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持